Promising New Therapy For MS Patients

An article posted early online from the Archive of Neurologyreports on a promising new treatment for people with multiple sclerosis(MS). Researchers have found that high doses of the drugcyclophosphamide, an immunosuppressant, have reduced MS activity anddisability in people with an aggressive form of the disease.

DioGenix Discovers Gene Sets Which Correlate To Multiple Sclerosis

Ore Pharmaceuticals Inc. (NASDAQ:ORXED) announced that DioGenix, its molecular diagnostics subsidiary, has identified novel sets of genes that it believes will form the basis of a new assay to diagnose multiple sclerosis (MS), a disease of the central nervous system (CNS).

HiCy Drug Regimen Reverses MS Symptoms In Selected Patients

A short-term, very-high dose regimen of the immune-suppressing drug cyclophosphamide seems to slow progression of multiple sclerosis (MS) in most of a small group of patients studied and may even restore neurological function lost to the disease, Johns Hopkins researchers report.

Significant Barriers Prevent People With MS From Fully Committing To Treatment Regimen, New Survey Reveals

Nearly all people (97 percent) with multiple sclerosis (MS) who have started treatment say their commitment to managing their disease in every way possible is their prime motivation for staying on therapy, according to a new North American survey of people with MS, results of which were released today at the Consortium of Multiple Sclerosis Centers annual meeting in Denver.

Bayer Schering Pharma Starts Global Awareness Campaign - Mastering MS

The results of an international survey presentedby Bayer Schering Pharma shows that many people face the same fears andconcerns when they are first diagnosed with multiple sclerosis (MS). In thesurvey, 71 percent of people with MS had at least one concern about how thedisease would affect their relationships;

FTY720 Trial Continues Despite Death, UK

Drug manufacturer Novartis has reported that two people with MS taking the oral drug fingolimod (FTY720) in clinical trials experienced problems with infections, leading to a fatality in one case. The firm said the role of the medicine in the cases was unclear and that the trial will continue.

MS Society Announces Media Award Winners, Canada

The Multiple Sclerosis Society of Canada announced the winners of its annual John Alexander Media Awards, recognizing excellence in print and broadcast journalism. The awards were established to honour the late John Alexander's contribution to increasing public awareness of MS in Canada.

EXTAVIA Approved In European Union For Treatment Of Multiple Sclerosis, First In Planned Portfolio Of Therapies From Novartis

The European Commission has approved Extavia (interferon beta-1b) for the treatment of early and relapsing forms of multiple sclerosis (MS) - the first in a new portfolio of medicines from Novartis that is planned to include both established treatments and innovative therapies for patients with MS.

MS Society Co-Funding Physio Posts To Meet Demand, UK

The MS Society is funding specialist MS physiotherapist posts to meet a need demonstrated by people living with multiple sclerosis (MS), and to combat NHS cuts.In an interview on the BBC Radio 4 You and Yours programme, MS Society chief executive, Simon Gillespie, said that the charity was increasingly having to fund physiotherapy posts at a cost of ^Alb40, 000 each due to a shortage.

Multiple Sclerosis Activity May Be Affected By Prozac

A new study published in the Journal ofNeurology Neurosurgery and Psychiatry finds that Prozac, acommonly prescribed antidepressant, may be an agent in slowingdown the disease process of the relapsing remitting form of multiplesclerosis (MS).Multiple sclerosis is an autoimmune disease where the immune systemattacks the central nervous system.